Sirona Biochem

Press Rodan and Fields

Press Release- Rodan and Fields + Sirona License

VANCOUVER, British Columbia, March 10, 2021 /CNW/ – Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (US-OTC: SRBCF) is pleased to announce the release of the first commercial product containing TFC-1067, the Company’s proprietary ingredient. TFC-1067 will be the active ingredient in Rodan + Fields REVERSE Targeted Dark Spot Corrector for the first time. It will specifically target stubborn discolouration to achieve a lighter, more uniform skin tone.

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Sirona Press Rodan and Fields

Press Release Rodan
and Fields + Sirona Biochem

Sirona licenced TFC-1067 to Rodan + Fields in 2019.

Rodan and Fields REVERSE Targeted Dark Spot Corrector achieved the following results in Rodan + Fields clinical trials*:

  • After 4 weeks, 77% had less apparent dark spots.
  • After 8 weeks: 72 per cent felt their dark spots were not the first thing people found. Rodan and Fields further claims:

Reduces the exposure of stubborn dark spots without leaving a halo

Dark spots that refuse to go away appear smaller, less established, and less severe.

  • The skin tone is more uniform and even.
  • Dark spots that refuse to go down are less prominent and less obvious.
  • Skin becomes clearer and more transparent.

Sirona has recently collaborated with a top-ten pharmaceutical firm to perform a European clinical trial to evaluate the efficacy of TFC-1067 at.4%. The 12-week analysis was successfully completed in February. The findings are being compiled into a final report, which will be published in the coming weeks.

“After comprehensive research, Rodan + Fields’ use of TFC-1067 in their latest REVERSE Targeted Dark Spot Corrector is the best validation of our technology to date. Rodan + Fields expects its customers to receive products that are both excellent and innovative. TFC-1067 is the foundation for a product that can uniquely brighten dark spots without leaving a halo effect,” said Sirona Biochem CEO Dr Howard Verrico. “Our long-term aim is to provide an appropriate alternative to hydroquinone for people looking for a solution to skin discolouration.


Press Release Rodan
and Fields + Sirona Biochem

We have shown that we can take a compound from the laboratory to clinical trials to large-scale development and incorporation into a commercial product with this launch. This validates our business model, and we want to take the same direction for the rest of our pipeline. This game-changing event is just the beginning of Sirona Biochem’s transformation into a sustainable, widely diversified large corporation.”

*Based on an 8-week clinical and market analysis conducted in the United States. The following factors can influence the outcome: age, gender, skin type and condition, concurrent products used, health history, place, lifestyle, and diet.

What Is TFC-1067?

TFC-1067, Sirona’s patented drug, outperforms current market actives while remaining safe and hydroquinone-free. The compound has undergone comprehensive clinical and preclinical testing, including a double-blind analysis for dyschromia in the United States and a new trial in the European Union for a higher dose. Clinical studies have shown that the compound outperforms hydroquinone in treating dyschromia while having no side effects.

Rodan + Fields is a cosmetics company based in California.

Rodan + Fields was founded in 2002 by Stanford-trained dermatologists Dr Katie Rodan and Dr Kathy Fields to provide customers with the best skin of their lives. The Doctors’ understanding that healthy skin empowers people to feel positively inspired by the creation of the brand. Rodan + Fields, founded in the digital age and built to meet consumers where they live and shop through mobile and social networks, disrupt the industry with its regimen-based skincare and powerful Independent Consultant group.

Please visit for more information.

Sirona Biochem Corp. is an acronym for Sirona Biochem Corporation.

TFC-1067, Sirona’s proprietary compound, is a cosmetic ingredient and drug development firm with its own platform technology. Sirona specialises in carbohydrate molecule stabilisation to increase efficacy and safety. To maximise sales potential, new substances are patented.

Sirona’s compounds are licenced to leading companies worldwide to exchange licencing fees, milestone fees, and continuing royalties. TFChem, Sirona’s laboratory in France, has received several French national science awards and European Union and French government grants. Please visit for more information.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as specified in the TSX Venture Exchange) accept responsibility for this publication’s sufficiency or accuracy.


Press Release Rodan and Fields



Phone: + 61 411 597 018
97 Collier Road, Embleton Western Autralia
MON-FRI 09:00 - 17:00,